ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
MOMA Therapeutics has launched with $86 million in series A financing, led by Third Rock Ventures, to develop small-molecule drugs against a family of more than 400 proteins—MOMA calls them molecular machines—that use ATP hydrolysis to “generate force and motion.” Examples include DNA helicases and chromatin remodeling proteins, which regulate gene expression. The company has recruited experts in protein biophysics and cryogenic electron microscopy to target molecular machines implicated in cancer and rare diseases.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X